Clinical Trial Search

Primary: Major Molecular Response Rate (MMR) at 12 Months Between All 3 Arms - With Imputation — 22.3; 44.3; 42.7 Percentage of participants — p=<0.0001

Primary: Percentage Change in Trunk Fat Mass (Defined as Peripheral Fat Ratio) — 0.366; 1.011 percent change — p=0.849

Primary: LDL Cholesterol — 103; 97 mg/dL

Primary: Best Spectacle-corrected Visual Acuity (BSCVA) in logMAR at 3 Months, Using Best Spectacle-corrected Enrollment Visual Acuity as a Co-variate — 0.48; 0.49 logMAR — p=0.82

Primary: Number of Participants With Response ( > 25% Reduction in T2 Flair) From Baseline to Evaluation at 6 Weeks Post Treatment — 5; 6 participants

Primary: Percentage of Participants Showing 10 Percent or Higher Response in Scoring Clinical Index for Onychomycosis (SCIO) Score at Week 5 — 25.6 percentage of participants

Primary: Percent of Subjects Who Develop Diabetes — 9; 12 percentage of participants — p=0.61

Primary: All Users Pregnancy Rates Based on Pearl Index (PI) Analyses for 91-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight — 2.82; 2.46; 4.54…

Primary: Irritability Subscale of the Aberrant Behavior Checklist, Community Version — -8.9 Points on a scale

Primary: Side Effects of Salsalate — 3 participants

Primary: Progression Free Survival (PFS) — 4.8; 2.4; 5.8; 2.9 Months

Primary: Surgical Site Infection — 13; 33 percentage of participants with SSI

Primary: Number of Participants With Graft Failure — 1 participants

Primary: Number of Participants With Adverse Events (AE) — 154; 138; 151; 5 participants

Primary: Proportion of Subjects With Major Response, i.e. Inhibitor Level Falls to Less Than 5 BU/mL Between Weeks 6 to 22 and Remains Below 5 BU/mL at 5-7 Days Following…